Seelos Therapeutics Inc (SEEL)

[mean gene]

On the conference call during the question and answer portion Pascoe indicated it may be sooner for the approval of Vitaros in the U.S. It all depends on the FDA and its meeting times. He also indicated there may be launches or approvals this month. The push for Vitaros as a first line of treatment sounds very promising. He said they are running at a burn rate of a 100k per month, not exactly a panic situation with 6m on hand.